Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Short term Debt (2022 - 2025)

Rxo (RXO) has disclosed Short term Debt for 4 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt changed 0.0% year-over-year to $17.0 million, compared with a TTM value of $17.0 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $17.0 million, changed 0.0% over the prior year.
  • Short term Debt was $17.0 million for Q4 2025 at Rxo, up from $16.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $17.0 million in Q4 2024 and bottomed at $3.0 million in Q3 2023.
  • Average Short term Debt over 4 years is $10.9 million, with a median of $15.5 million recorded in 2024.
  • The sharpest move saw Short term Debt plummeted 40.0% in 2023, then soared 466.67% in 2024.
  • Year by year, Short term Debt stood at $4.0 million in 2022, then fell by 25.0% to $3.0 million in 2023, then skyrocketed by 466.67% to $17.0 million in 2024, then changed by 0.0% to $17.0 million in 2025.
  • Business Quant data shows Short term Debt for RXO at $17.0 million in Q4 2025, $16.0 million in Q3 2025, and $16.0 million in Q2 2025.